RECOVER I: IMPELLA® RECOVER® LP/LD 5.0 Support System: A Clinical Safety & Feasibility Study
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Cardiac Surgery
- Sponsor
- Abiomed Inc.
- Enrollment
- 17
- Locations
- 7
- Primary Endpoint
- Frequency of Major Adverse Events
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
To demonstrate that that the device is safe and potentially efficacious for use as a left ventricular cardiac assist device for postcardiotomy patients who require hemodynamic support post weaning from cardiopulmonary bypass.
Detailed Description
To demonstrate that the device is safe and potentially efficacious for use as a left ventricular cardiac assist device for postcardiotomy patients who require hemodynamic support post weaning from cardiopulmonary bypass. Postcardiotomy patients, weaned from a cardiopulmonary bypass system (CPB) in need for hemodynamic support due to ineffective standard medical therapy will be considered for enrollment. An attempt shall be made to reverse the hemodynamic situation with medications (e.g. inotropes, vasopressors). The IMPELLA RECOVER LP/LD 5.0 will be implanted by the surgeon when no improvement in hemodynamics is observed.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Receiving stable infusion of one high dose inotrope or two medium dose inotropes for a respective minimum time indicated.
- •Elevated Filling Pressures, PCWP or PA
- •Time to enrollment within 48 hours from weaning
Exclusion Criteria
- •Renal dysfunction
- •Hepatic dysfunction
- •Right Ventricular failure defined.
- •LV or RV Thrombus
- •Other exclusions per protocol
Outcomes
Primary Outcomes
Frequency of Major Adverse Events
Time Frame: 30 day or discharge
Secondary Outcomes
- Other Adverse Events Doppler echocardiography assessment of aortic valve function will be performed at explant and 30days and 3 month follow-ups.(3 months)